CYP2C19 genotypes and Helicobacter pylori eradication

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 8 PART1, 2008, Pages 1163-

  Sheu, Bor Shyang ^a   Fock, Kwong Ming ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANTIBIOTIC RESISTANCE; ASIA; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DNA POLYMORPHISM; DRUG DOSE INCREASE; EDITORIAL; ERADICATION THERAPY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL;

EID: 48549090855     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05519.x     Document Type: Editorial

References (9)

1. Malfertheiner P, Megraud F, Morain CO et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus report. Aliment. Pharmacol. Ther. 2002 16 : 167 80.
2. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 81.
3. Teo EK, Fock KM, Ng TM, Khor CJL, Tan AL. Metronidazole-resistant Helicobacter pylori in an urban Asian population. J. Gastroenterol. Heptaol. 2000 15 : 494 7.
4. Sheu BS, Kao WA, Cheng HC et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment. Pharmacol. Ther. 2005 21 : 283 8.
5. Kang JM, Kim NY, Lee DH et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J. Gastroenterol. Hepatol. 2008 23 : 1287 91.
6. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 4.
7. Dojo M, Azuma T, Saito T et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton-pump inhibitor (omeprzole or rabeprazole), amoxicillin, and clarithromycin in Japan. Digest. Liver Dis. 2001 33 : 671 5.
8. Miki I, Aoyama N, Sakai T et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur. J. Gastroenterol. 2003 15 : 27 33.
9. Kuwayama H, Asaka M, Sugiyama T et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large scale study in Japan. Aliment. Pharmacol. Ther. 2007 25 : 1105 13.